NovoCure Limited

NovoCure Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, NovoCure Ltd. has 116.44M shares outstanding.

As of June 30, 2026, NovoCure Ltd. maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, NovoCure Ltd. posted a negative return on equity (ROE) of -43.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -14.56, reflecting losses generated across the asset base. The company generates approximately 7.75M in revenue per employee across its workforce of 1,575.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.05 indicates how many times NovoCure Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, NovoCure Ltd. recorded an income tax benefit of -72.00M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.67B and -2.60B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 15, 2026, NovoCure Ltd.'s stock has declined approximately 16.61% over the past 52 weeks.

Over the twelve months ended June 30, 2026, NovoCure Ltd. generated 12.22B in revenue and converted that into -2.60B in net income, yielding earnings per share of -22.85. EBITDA reached -2.41B, while operating income came in at -2.70B.

As of June 30, 2026, NovoCure Ltd. holds 7.70B in cash and equivalents against 4.08B in total debt, resulting in a net debt position of 1.79B. Total book value stands at 5.91B, with working capital of 7.30B providing operational flexibility.

NovoCure Ltd. produced -49.18M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -395.19M in capital expenditures, free cash flow totaled -444.37M - equivalent to -3.91 per share.

Over the twelve months ended June 30, 2026, NovoCure Ltd. posted a gross margin of 76.13, reflecting its pricing power and cost economics. The operating margin of -22.08 and net profit margin of -21.25 provide insight into operational efficiency.